India’s first messenger mRNA vaccine is expected to begin human trials in February. The Pune-based Gennova Biopharmaceuticals has submitted Phase 2 data of mRNA vaccine and has also completed the recruitment of Phase 3 data. The official sources said that the Drugs Controller General of India’s (DCGI) Subject Expert Committee (SEC) is expected to review the data soon.
Gennova Biopharmaceuticals has also developed the mRNA vaccine for the Omicron variant that will be tested on humans for efficacy and immunogenicity soon, the official sources said.
Earlier in September 2021, Gennova issued a press statement and updated about the vaccines trials, “The Drug Controller General of India had approved Phase II and Phase III study protocols for HGCO19, India’s first mRNA-based COVID-19 vaccine, developed by Gennova Biopharmaceuticals Limited (“Gennova”) back in August.”
“Gennova had submitted the interim clinical data of the Phase I study to the Central Drugs Standard Control Organisation (CDSCO), the Government of India’s National Regulatory Authority (NRA). The Vaccine Subject Expert Committee (SEC) had reviewed the interim Phase I data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study,” it said.
The company also mentioned the number of trials sites, “The study is being conducted in India at approximately 10-15 sites in Phase II and 22-27 sites in Phase III. Gennova is using the DBT-ICMR clinical trial network sites for this study.”
mRNA vaccines belong to the category of nucleic acid vaccines, which use genetic material from disease-causing viruses or pathogens to trigger an immune response against it within the body.